–
Доклады на научных конференциях
-
- 2023 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes (Устный)
- Авторы: Harbeck N., Rastogi P.
- ESMO Congress 2023, Мадрид, Испания, 20-24 октября 2023
-
- 2023 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes (Устный)
- Авторы: Harbeck N., Rastogi P.
- ESMO Congress 2023, Мадрид, Испания, 20-24 октября 2023